Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.

You may also be interested in...



AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program

AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.

Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III

Reata has terminated the Phase III BEACON trial for its chronic kidney disease hopeful bardoxolone methyl, partnered with Abbott, due to safety concerns.

As AbbVie Prepares To Launch, Some Wind Gets Knocked Out Of Its Sails

Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.

Related Content

Topics

UsernamePublicRestriction

Register

PS072908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel